Effimune and In Cell Art collaborate to develop a novel therapeutic approach in immunology
PR 110216Final The two biotechnology companies in Nantes develop a novel approach aiming at the production of therapeutic antibodies directly... View Article
Atlanpole Biotherapies joins CEBR Board
The Council of European BioRegions (CEBR) is a network of biotechnology support professionals that support their local biocommunity through direct services including... View Article
Porsolt expands with the acquisition of Fluofarma
Porsolt has acquired Fluofarma, a Bordeaux-based company focused on the provision of cell-based assays and in vitro screening services. The... View Article
IFB-088 (Sephin1) receives orphan drug designation in the European Union for the treatment of Charcot-Marie-Tooth disease
InFlectis BioScience announces that the European Commission has granted orphan drug designation to its drug candidate IFB-088, also known as... View Article
CESTI IHU: Predicting transplant rejection to better anticipate it
The objectives of the programs led by Dr. Sophie Brouard and Pr. Antoine Magnan within the CESTI IHU are to... View Article
Maryvonne Hiance elevated to the rank of Officer of the Legion of Honor
Maryvonne Hiance, Vice President of Atlanpole Biotherapies cluster and manager of Effimune, was given the insignia of Officer of the... View Article
A New member: Gammeo
Gammeo enables the monitoring of all property issues related to a health facility through a simple and intuitive web interface.... View Article
The attraction of CESTI IHU has been the establishment of a professorial position specifically for Pierre-Antoine Gourraud
Professor Pierre-Antoine Gourraud, a recognized specialist in the fields of immunology, genetics and bioinformatics, leaves his position of Associate Professor... View Article
FIRM project was funded at the level of 15 million euros
FIRM project is aimed at the development of an industrial sector producing innovative radioisotopes for medical use. Coordinated by the... View Article
Valneva Reports Positive Phase II Results for its Clostridium Difficile Vaccine Candidate
Valneva SE, a leading pure-play vaccine company, announced today, positive Phase II results for its prophylactic vaccine candidate against Clostridium... View Article